Recurrence of hepatitis C infection: Where are we now?

Area of Science:

• Hepatology
• Transplantation Immunology
• Virology

Background:

• Hepatitis C-associated liver failure is a primary indication for liver transplantation.
• Recurrent Hepatitis C Virus (HCV) infection leads to graft loss or death in approximately 10% of liver transplant recipients.
• Understanding recurrence is crucial for improving long-term outcomes in liver transplant patients.

Purpose of the Study:

• To identify risk factors associated with histological recurrence of Hepatitis C Virus (HCV) post-liver transplantation.
• To summarize current treatment strategies for post-transplant HCV recurrence.
• To highlight the evolving role of immunoglobulins in managing HCV recurrence.

Main Methods:

• Review of literature on risk factors for HCV recurrence after liver transplantation.
• Analysis of donor-related factors (age, fat content, ischemic time, donor type).
• Evaluation of recipient-related factors (age, race), clinical factors (rejection, CMV), and viral factors (viral load, quasispecies).

Main Results:

• Identified multiple risk factors for HCV recurrence, including donor age, fat content, and ischemic time.
• Recipient factors such as age and non-Caucasian race were associated with increased risk.
• Clinical factors like rejection and CMV infection, along with viral load and quasispecies, also correlated with recurrence.

Conclusions:

• Histological recurrence of HCV post-liver transplant is influenced by a combination of donor, recipient, clinical, and viral factors.
• Current treatment involves pegylated interferon with or without ribavirin.
• Further research is needed to define the role of hepatitis C immunoglobulin in managing post-transplant HCV.